Skip to main content

Free Content Targeting the Nogo Receptor Complex in Diseases of the Central Nervous System

Download Article:
(PDF 290.7 kb)


After injury to the central nervous system intrinsic factors such as myelin associated inhibitory factors inhibit cellular and axonal regeneration resulting in permanent disability. Three of these factors (Nogo-A, oligodendrocyte myelin glycoprotein, myelin-associated glycoprotein) bind to a common receptor: the Nogo-66 receptor (NgR1). NgR1 is expressed mainly on neurons and is usually associated in a trimolecular complex. The second member of the complex, LINGO-1, is often connected to NgR1 function and is further found to function independently as a negative regulator of oligodendrocyte proliferation and differentiation. The third member of the NgR complex is either the p75 neurotrophin receptor, TROY, or an as yet unidentified co-receptor. Targeting of factors contained in this complex has been described to lead to the promotion of neurite outgrowth, oligodendrocyte proliferation and differentiation and inhibition of cell death. In the current review, we aim to describe the mechanisms of action of the chemical and biological compounds used in targeting NgR1 and LINGO-1. This will be achieved using three examples: blocking of ligand binding to NgR1 in treatment of spinal cord injury, antibody-mediated inhibition of LINGO-1 to promote oligodendrocyte differentiation in multiple sclerosis, and the use of soluble NgR1 to sequester Abeta peptide in the periphery in Alzheimer's disease.

Keywords: Alzheimer's disease; B lymphocyte stimulator; Interferon-s; LINGO-1; Multiple Sclerosi; Parkinson's disease; Purkinje cells; Schwann cell grafts; alka-line phosphatase (AP); amyloid peptide; blood-brain barrier; central nervous system intrinsic; chondroitin sulphate proteoglycans; corticospinal tract; erythropoietin; glatiramir acetate; glucocorticosteroids; glycoprotein; glycosylphosphatidylinositol; guanosine triphosphatase; hippocampal neurons; hybridization; immunohistochemis-try; intravenous steroids; minocyclin; multiple sclerosis; mutagenesis; myelin associated inhibitory factors; myelination; neurotrophin receptor; nogo receptor; olfactory nervous system; oli-godendrocyte; oligodendrocyte mye-lin glycoprotein; oligodendrocyte precursor; proteolipid protein; remyelination; sclerosis; serotonergic axon; spinal cord injury; thoracic spinal cord

Document Type: Research Article


Publication date: January 1, 2011

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more